mercredi 14 juin 2017

Onco Actu du 14 juin 2017

3.5 Prévention - UV

Mass. General-led study replicates tanning response in cultured human skin [Mass. General Hospital]

Could this new compound give you a suntan—without the sun? [Science]

Scientists create ‘fake’ tan which could protect against skin cancer [The Guardian]

5.12.1 Immunothérapies - partenariats

OSE, Memorial Sloan Kettering Cancer Center ally to advance anti-CD127 NSCLC candidate [FierceBiotech]

5.12.2 Immunothérapies - CAR-T

Rising Penn star Saar Gill gets funding for a next-gen CAR-T startup, adding a new weapon to the mix [EndPoints]

For experimental cancer therapy, a struggle to ensure supply keeps up with demand [Science]

5.12.5 Immunothérapies - Pharma

Cancer vaccine developer Targovax pulls in €21M in private placement (FiercePharma]

5.2.2 Pharma - Fusions & Acquisitions

Sanofi, Gilead said to be eyeing potential $10B deal for prime cancer target Tesaro [FiercePharma]

Buyout Buzz: Sanofi, Gilead rumors keep the fire burning under a boiling Tesaro buyout story [EndPoints]

5.2.3 Pharma - économie

Pfizer, Roche cancer drug pricing under investigation in South Africa [FiercePharma]

Pfizer, Roche and Aspen face South Africa probe over cancer drug prices [Reuters]

5.4 Traitements - Economie

Drug costs vary by more than 600% in study of 10 high-income countries [European Pharmaceutical Review]

Government negotiation of prescription drug prices isn’t a panacea for lower costs [STAT]

5.5 ASCO

Getting Personal at ASCO 2017: Precision Therapies, IO, and Autologous Cell Therapy [Life Sci VC]

6.1 Observation

Genomic Study Seeks Clues to Help Explain Breast Cancer Disparities [NCI]

Mammogram follow-up tests take longer for Asian women in U.S. [Reuters]

6.8 Communication

Conflicts of interest: Time for world’s top health journalism organization to reconsider fundraising practices. Part 2 of 3 [HealthNewsReview]

6.9 Controverses

Can fake names tease out NIH reviewer bias? [Science]